In breast cancer, particularly basal-like breast cancer (BLBC), aberrant glycosylation of B3GNT5 enhances cancer stem cell properties, increasing invasiveness and resistance to therapy [344]. This evidence concerns the gene B3GNT5 and breast carcinoma.